Article in Science translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
8 citing papers in PubMed, 6 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors at 6 institutions in 2 countries.
Sherly I CeladaDepartment of Biological Sciences, Tennessee State University, Nashville, TN 37209, USA.ORCID 0009-0004-7064-1855
Clarice X LimCenter of Pathobiochemistry and Genetics, Institute of Medical Genetics, Medical University of Vienna, Vienna 1090, Austria.ORCID 0000-0001-7297-0055
Alexandre F CariseyWilliam T. Shearer Center for Human Immunobiology, Texas Children's Hospital, Houston, TX 77030, USA.ORCID 0000-0003-1326-2205
Scott A OchsnerDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.ORCID 0000-0003-1099-7863
Carlos F Arce DezaDepartment of Medicine, Section of Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
Praveen RexieCenter of Pathobiochemistry and Genetics, Institute of Medical Genetics, Medical University of Vienna, Vienna 1090, Austria.ORCID 0000-0001-6388-6716
Fernando Poli De FriasDepartment of Medicine, Section of Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
Rafael Cardenas-CastilloDepartment of Medicine, Section of Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, TX 77030, USA.ORCID 0000-0003-2749-3565
Francesca PolverinoDepartment of Medicine, Section of Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
Markus HengstschlägerCenter of Pathobiochemistry and Genetics, Institute of Medical Genetics, Medical University of Vienna, Vienna 1090, Austria.
Konstantin TsoyiDepartment of Medicine, Section of Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
Neil J McKennaDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.ORCID 0000-0001-6689-0104
Farrah KheradmandDepartment of Medicine, Section of Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, TX 77030, USA.ORCID 0000-0001-5343-103X
Thomas WeichhartCenter of Pathobiochemistry and Genetics, Institute of Medical Genetics, Medical University of Vienna, Vienna 1090, Austria.ORCID 0000-0002-4349-0797
Ivan O RosasDepartment of Medicine, Section of Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, TX 77030, USA.ORCID 0000-0003-4622-618X
Luc Van KaerDepartment of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.ORCID 0000-0001-5275-2309
Lindsay J CeladaDepartment of Medicine, Section of Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
Baylor College of Medicine · USMedical University of Vienna · ATMichael E. DeBakey VA Medical Center · USSt. Jude Children's Research Hospital · USTennessee State University · USVanderbilt University · US
Funding
Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ben Ho Park · 1995 to 2026
$172.8M
Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Suzanne AW Fuqua · 2007 to 2026
$73.9M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MARY Kay WASHINGTON · 2002 to 2026
$29.9M
Respiratory Computational Discovery CoreP01HL114501 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI SILVERMAN, EDWIN K · 2013 to 2025
$24.9M
RESPIRATORY RESEARCHT32HL007633 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI George R Washko · 1985 to 2026
$14.9M
Role of autophagy-related protein Vps34 in antigen presentation and self-toleranceR01AI139046 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI VAN KAER, LUC · 2019 to 2023
$2.2M
Mentoring in Translational Research in Interstitial Lung DiseasesK24HL127301 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Wonder P. Drake · 2016 to 2026
$1.2M
CD8+ T Cell Dysfunction Promotes Sarcoidosis ProgressionK01HL145338 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CELADA, LINDSAY JOHANA · 2019 to 2023
$673k
BD Biosciences Special Order LSRIIS10RR024574 · NCRR · BAYLOR COLLEGE OF MEDICINE · PI LUMPKIN, ELLEN A · 2009 to 2009
Sarcoidosis is an interstitial lung disease (ILD) characterized by interferon-γ (IFN-γ) and T-box expressed in T cells (TBET) dysregulation. Although one-third of patients progress from granulomatous inflammation to severe lung damage, the molecular mechanisms underlying this process remain unclear. Here, we found that pharmacological inhibition of phosphorylated SH2-containing protein tyrosine phosphatase-2 (pSHP2), a facilitator of aberrant IFN-γ abundance, decreased large granuloma formation and macrophage infiltration in the lungs of mice with sarcoidosis-like disease. Positive treatment outcomes were dependent on the effective enhancement of TBET ubiquitination within CD8
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
SHP2 promotes sarcoidosis severity by inhibiting SKP2-targeted ubiquitination of TBET in CD8 · full record | OpenQuestion